NCT01474499已完成3 期
A Multi-center, Randomized, Single-blind Clinical Study of the Comparative Safety and Efficacy of Docusate Sodium and Sorbitol Rectal Solution and Glycerine Enemas in Patients With Constipation
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 9
- 主要终点
- Overall efficacy rate of the enema in treating the symptoms of constipation
研究概览
简要总结
This study aims to evaluate the efficacy and safety of the docusate sodium and sorbitol rectal solution produced by Ferring Pharmaceutical (China) Ltd. in treating Chinese patients with constipation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have signed the informed consent form and have been verbally told of the details of the trial and treatment procedures
- •Is a citizen of the People's Republic of China
- •Males and females aged between 18 and 65 years inclusive
- •A history of constipation symptoms for at least 6 months, with occurrence of two or more of the symptoms during the 3 months before screening:
- •More than 1/4 of stool classifiable as Type I or Type II on the Bristol Stool Scale;
- •Sensation of incomplete evacuation at least 1/4 of the time;
- •Straining during defecation at least 1/4 of the time;
- •Sensation of ano-rectal blockage or obstruction during defecation at least 1/4 of the time;
- •Manual manoeuvres needed often to facilitate defecations (e.g. digital evacuation) at least 1/4 of the time;
- •Fewer than 3 bowel movements per week
- •No bowel movement within two days prior to randomisation
排除标准
- •Patients who are suspected to have colorectal cancer;
- •Patients showing signs of bleeding in the digestive tract or inflammatory bowel disease;
- •Patients experiencing abdominal discomfort or intestinal blockage for which the cause has yet to be determined;
- •Patients allergic to docusate or sorbitol;
- •Patients allergic to glycerine;
- •Those pregnant, breastfeeding, or with the intention of becoming pregnant, or fertile women who are not on effective birth control（i.e. an IUD (intrauterine device), oral contraceptives or other obstructive measures;
- •Severe liver damage (ALT (alanine aminotransferase), AST (aspartate transaminase), TBIL (serum total bilirubin) more than 2 times the upper limit of normal)
- •Kidney function impairment (Cr (creatinine clearance rate), BUN (blood urea nitrogen) more than 1.5 times the upper limit of normal)
- •Patients who have participated in any other clinical trial during the last 3 months;
- •Diabetics who are currently undergoing insulin treatment;
- •Patients who are unable to suspend using treatments that affect the kinetics of the digestive system in the 5 days prior randomisation. Such treatments include prokinetic drugs, erythromycin analogues, laxatives, etc;
- •Other patient factor(s) (e.g. medical history, concurrent illness(es), laboratory test result(s), etc.) at Screening that in the opinion of the investigator(s) would put the trial patient at excessive risk;
- •Patients who are unable to act in a legal capacity, unable to meet or perform study requirements, or are known or suspected as unable to comply with the study protocol.
研究组 & 干预措施
Glycerine
Active Comparator
干预措施: Glycerine (Drug)
Docusate sodium and sorbitol rectal solution
Experimental
干预措施: Docusate sodium and sorbitol rectal solution (Drug)
结局指标
主要结局
Overall efficacy rate of the enema in treating the symptoms of constipation
时间窗: Up to 30 minutes
次要结局
- Patient's overall assessment of using the enema to treat the symptoms of constipation(Up to 30 minutes)
- Abdominal pain (absent, mild, moderate, or severe)(Up to 30 minutes)
- Time from conclusion of enema administration to patient's first bowel movement(Up to 30 minutes)
- Amount of straining that occurs during bowel movement (normal/difficult)(Up to 30 minutes)
- Feeling of emptying of the rectum post bowel movement (complete/incomplete)(Up to 30 minutes)
- Stool form after enema treatment according to Bristol Stool Scale(Up to 30 minutes)
- Anal complaints (absent, anal itch, anal irritation or anal pain)(Up to 30 minutes)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
不适用
Effectiveness of Docusate in Preventing/Treating Constipation in Palliative Care PatientsPalliative CareConstipationNCT00902031University of Alberta70
已完成
2 期
A Study for Patients With Relapsing Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisNCT00869986Eli Lilly and Company218
已完成
3 期
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionDepressive DisorderNCT00256113Sanofi467
已完成
3 期
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionDepressive DisorderNCT00250601Sanofi460
已完成
3 期
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionDepressive DisorderNCT00250614Sanofi452